Calliditas, a pharmaceutical company headquartered in Sweden, has appointed Andrew Udell as new Vice President (VP) of Commercial, North America, effective 1 February 2019. His appointment comes in time to lead the commercial launch of the company’s new niche nephropathy treatment, Nefecon.
Prior to his appointment, Udell was VP Commercial for North America at Neuroderm, until to the Company’s US$1.1bn acquisition by Mitsubishi Tanabe Pharma. Before this, he was in commercial leadership roles in the biotech industry, including at Intrexon Corporation and Clinical Data, where he was responsible for the US commercial launch of Viibryd, an antidepressant.
Commenting on his appointment Udell said: “I look forward to working with the team at Calliditas to design and execute a successful US commercial strategy for this promising treatment option.”
With multiple leadership roles in billion-dollar companies, Udell will bring much to the VP Commercial role. Renée Aguiar-Lucander, Calliditas Therapeutics CEO, said: “His successful track record of transitioning research and development phase organizations to commercial stage companies will be a key asset as we build out our US commercial presence in advance of launching Nefecon”.
